跳至主要内容
临床试验/NCT03299751
NCT03299751已完成不适用

Evaluation of Biomarkers Combination Performance for the Diagnosis of Neonatal Sepsis in NICU Hospitalized Newborns

Hospices Civils de Lyon2 个研究点 分布在 1 个国家目标入组 233 人开始时间: 2017年11月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
233
试验地点
2
主要终点
LOS diagnosis in NICU newborns of at least 7 days of life with suggestive clinical signs, confirmed by adjudication committee

研究概览

简要总结

Late-onset neonatal sepsis (LOS), occurring in newborn of at least 7 days of life, is frequently observed in Neonatal Intensive Care Units (NICUs) and potentially severe (mortality, neurologic and respiratory impairments).

Despite its high prevalence, a reliable diagnostic remains difficult. Currently, nonspecific clinical signs that might be linked to other neonatal conditions, such as prematurity and birth defects are used to determine the diagnosis of LOS. Laboratory results of biological markers, such as C-Reactive Protein (CRP) and Procalcitonin (PCT) are often delayed in comparison with LOS onset. Blood culture results are too late and lack sensitivity.

Excessive antibiotic use is observed in a large proportion of NICU hospitalized newborns. This results in an increased antibiotic resistance, microbiota modification, neonatal complications (pulmonary, ophthalmologic and neurologic) and mortality.

The primary objective is to identify, on a cohort of 250 patients, the optimal biomarker combination with good diagnostic performance (i.e. with maximal Area Under the ROC Curve) to early exclude a LOS diagnostic in newborns of at least 7 days of life with suggestive signs.

This identification will be carried out, as a secondary objective, with a sub-group of pre-term neonates whose birth weight is less than 1500 grams. The diagnostic value of the clinical signs that are suggestive of LOS will also be determined (sensitivity, specificity, negative and positive predictive values).

Once identified, the biomarker combination is expected to reduce unjustified antibiotic use.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
7 Days 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients hospitalized in NICU;
  • patients with suggestive signs of LOS including at least one of the following:
  • o Fever > 38°C; tachycardia > 160bpm160 bpm; capillary refill time > 3 seconds; grey and/or pale skin complexion; apnea/ bradycardia syndrome,; bloating; rectal bleeding; hypotonia; lethargy; seizures without other obvious cause; increased ventilatory support and/or increased FiO2; cutaneous rash; inflammation at the needle-puncture site of the central venous catheter;
  • patients with a standard of care blood sampling, including at least a blood culture;
  • consent form signed by at least one parent/ legal representative.

排除标准

  • patients treated with antibiotics for a bacteriologically confirmed infection at the moment of/ or 48 hours before blood sampling
  • patients who underwent surgery during the 7 days prior to inclusion
  • patients vaccinated during the 7 days prior to inclusion

研究组 & 干预措施

NICU newborns of at least 7 days of life with suggestive signs

Experimental

干预措施: Diagnostic performances of biomarkers combination (Biological)

结局指标

主要结局

LOS diagnosis in NICU newborns of at least 7 days of life with suggestive clinical signs, confirmed by adjudication committee

时间窗: hour 48

The primary outcome measure will be determined by an independent adjudication committee that will classify the patients into the following categories: infected, not infected or unclassified patients. This committee will be blinded to the biomarkers that will be used to identify a combination with the best negative predictive value. It will be composed of two neonatologists and a pediatrician specialized in the child infectious diseases. The diagnostic performance of the biomarkers combination will be based on the adjudication committee

次要结局

  • LOS diagnosis in NICU preterm neonates, whose weight at birth is less than 1500 grams, of at least 7 days of life, with suggestive clinical signs, confirmed by adjudication committee.(Hour 48)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验